Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548894 | 0.93 | HDAC11 (0.32) | IDO1TDO2LMNAMEN1KMT2A | |
| SCHEMBL549636 | 0.92 | EPHX2 (0.30) | IDO1TDO2EPHX2 | |
| SCHEMBL548959 | 0.90 | MEN1 (0.31) | IDO1TDO2MEN1KMT2A | |
| SCHEMBL548991 | 0.88 | IDO1 (0.32) | IDO1TDO2MEN1KMT2AHDAC11 | |
| SCHEMBL548649 | 0.88 | CNR2 (0.31) | HDAC11CNR2 | |
| SCHEMBL549919 | 0.85 | IDO1 (0.32) | IDO1TDO2MEN1KMT2AHDAC11 | |
| SCHEMBL549953 | 0.85 | HDAC11 (0.30) | HDAC11 | |
| SCHEMBL548687 | 0.84 | MEN1 (0.33) | EPHX2NPC1LMNAALDH1A1MEN1 | |
| SCHEMBL549675 | 0.83 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL549007 | 0.82 | HDAC11 (0.37) | IDO1TDO2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110614-B2 | Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative | IDEMITSU KOSAN CO., LTD. (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100056663-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | IDEMITSU KOSAN CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2090563-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | IDEMITSU KOSAN COMPANY LIMITED (JP) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056663-A1 | ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE | ARCN1, RTN3, CHRNA3 | IDO1 4291/4885TDO2 3401/4885EPHX2 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.